Cullinan Oncology is a biopharmaceutical company developing first- or best-in-class therapies for autoimmune diseases and cancer, with core expertise in T cell engagers. The company's pipeline includes CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune indications such as systemic lupus erythematosus and rheumatoid arthritis; CLN-049, a FLT3xCD3 bispecific T cell engager for acute myeloid leukemia and myelodysplastic syndrome; zipalertinib, an oral EGFR inhibitor for non-small cell lung cancer developed through a collaboration with Taiho; and velinotamig, a licensed BCMAxCD3 bispecific T cell engager for autoimmune diseases. The company generates revenue through milestone payments and profit-sharing arrangements with partners, particularly from its Taiho collaboration, while advancing its proprietary programs through clinical trials. Cullinan competes against larger pharmaceutical companies across multiple therapeutic areas and differentiates itself through its specialized expertise in T cell engager technology and manufacturing partnerships with contract manufacturers globally.